排序方式: 共有35条查询结果,搜索用时 15 毫秒
1.
Recognition of a subregion of human proinsulin by class I-restricted T cells in type 1 diabetic patients 下载免费PDF全文
Toma A Haddouk S Briand JP Camoin L Gahery H Connan F Dubois-Laforgue D Caillat-Zucman S Guillet JG Carel JC Muller S Choppin J Boitard C 《Proceedings of the National Academy of Sciences of the United States of America》2005,102(30):10581-10586
Proinsulin is a key autoantigen in type 1 diabetes. Evidence in the mouse has underscored the importance of the insulin B chain region in autoimmunity to pancreatic beta cells. In man, a majority of proteasome cleavage sites are predicted by proteasome cleavage algorithms within this region. To study CD8+ T cell responses to the insulin B chain and adjacent C peptide, we selected 8- to 11-mer peptides according to proteasome cleavage patterns obtained by digestion of two peptides covering proinsulin residues 28 to 64. We studied their binding to purified HLA class I molecules and their recognition by T cells from diabetic patients. Peripheral blood mononuclear cells from 17 of 19 recent-onset and 12 of 13 long-standing type 1 diabetic patients produced IFN-gamma in response to proinsulin peptides as shown by using an ELISPOT assay. In most patients, the response was against several class I-restricted peptides. Nine peptides were recognized within the proinsulin region covering residues 34 to 61. Four yielded a high frequency of recognition in HLA-A1 and -B8 patients. Three peptides located in the proinsulin region 41-51 were shown to bind several HLA molecules and to be recognized in a high percentage of diabetic patients. 相似文献
2.
Lengagne R Le Gal FA Garcette M Fiette L Ave P Kato M Briand JP Massot C Nakashima I Rénia L Guillet JG Prévost-Blondel A 《Cancer research》2004,64(4):1496-1501
Tumor antigen-reactive T cells can be detected in a large proportion of melanoma patients, but their efficacy on tumor control in vivo remains unclear. On the other hand, vitiligo, a skin disorder characterized by patchy depigmented macules, may occur spontaneously or after antitumor therapies. Moreover, vitiligo is significantly associated with positive clinical response, but the mechanism is not understood. Therefore, the establishment of a relevant animal model in which melanoma and vitiligo spontaneously develop stepwise may be useful for better understanding of the parameters involved in the destruction of both benign and malignant melanocytes. In a previous work, we established a mouse model for melanoma in which MT/ret transgenic mice express the ret oncogene fused to the metallothionein promoter. Here we report that melanoma leads to spontaneous vitiligo. We further investigate, for the first time in this model, the natural antitumor T-cell response and evaluate the role of cellular immunity in the development of the disease. Interestingly, the occurrence of spontaneous tumor nodules in MT/ret mice with melanoma-associated vitiligo is significantly delayed when compared in melanoma mice without vitiligo. Moreover, a significant proportion of mice with melanoma-associated vitiligo resisted a challenge with syngeneic melanoma cells in contrast to animals without vitiligo. Our results confirm that vitiligo is associated with clinical benefit and further demonstrate the crucial role of CD8+ T cells for tumor control in melanoma-associated vitiligo. 相似文献
3.
Lévy Y Gahéry-Ségard H Durier C Lascaux AS Goujard C Meiffrédy V Rouzioux C El Habib R Beumont-Mauviel M Guillet JG Delfraissy JF Aboulker JP;ANRS Study Group 《AIDS (London, England)》2005,19(3):279-286
OBJECTIVE: Several lines of evidence suggest that the immune system may control HIV-1 replication, but that it could fail in the long term. Strategies aimed to elicit specific immune responses may enable patients to contain virus replication. METHODS: HIV-1-infected patients were randomized to continue either their antiviral therapy alone (controls; n = 37) or with four boosts of vaccination combining ALVAC-HIV (vCP1433) and Lipo-6T vaccines (weeks 0, 4, 8, 12) followed by three cycles of subcutaneous interleukin-2 (weeks 16, 24, 32) (Vac-IL-2 group; n = 34). RESULTS: Of the Vac-IL-2 group, 15/32 (47%) exhibited a stable HIV p24 antigen-proliferative response compared with 8/33 (24%) controls (P = 0.049). After vaccination, 19/33 (58%) of the Vac-IL-2 group exhibited a multiepitopic HIV-1-specific CD4 cell proliferative response compared with 9/36 (25%) of controls (P = 0.006). The breadth and the magnitude of HIV-specific interferon-gamma-producing CD8 T cells improved in the Vac-IL-2 group. After stopping antiviral drugs, 24% of the Vac-IL-2 group lowered their viral set point compared with 5% of controls (P = 0.027). Logistic-regression analysis demonstrated that vaccine-elicited immunological responses were predictive of virological control (P = 0.046 and 0.014 for stable and multiepitopic CD4 T cell responses, respectively). CONCLUSION: This study provides proof of the concept that therapeutic immunization before antiviral drug cessation may contribute to the containment of HIV replication. 相似文献
4.
Lévy Y Durier C Lascaux AS Meiffrédy V Gahéry-Ségard H Goujard C Rouzioux C Resch M Guillet JG Kazatchkine M Delfraissy JF Aboulker JP;ANRS Study Group 《AIDS (London, England)》2006,20(3):405-413
OBJECTIVE: Viral rebounds inevitably follow interruption of antiretroviral treatment in HIV-1-infected individuals. The randomized ANRS 093 aimed at investigating whether a therapeutic immunization was effective in containing the long-term viral replication following discontinuation of antiretroviral drugs in patients. METHODS: Seventy HIV-1-infected patients effectively treated with antiretroviral drugs were randomized to continue treatment alone or in combination with four boosts of ALVAC 1433 and HIV-LIPO-6T vaccines followed by three cycles of subcutaneous interleukin-2. The impact of vaccination on viral replication was assessed by interrupting antiretroviral drugs first at week 40 and thereafter during follow-up until week 100. Antiretroviral drugs were re-initiated according to predefined criteria. RESULTS: The median cumulative time (days) off treatment was greater in the vaccine group (177) than in the control group (89) (P = 0.01). The proportion of time (mean, SE) without antivirals per-patient was 42.8% (5.1) and 26.5% (4.2) in the vaccine and control groups, respectively (P = 0.005). Viremia (median log10 copies/ml), 4 weeks following the first, second and third treatment interruption was higher in control patients (4.81, 4.44, 4.53) in comparison with vaccinated patients (4.48, 4.00, 3.66) (P = 0.42, 0.015 and 0.024, respectively). HIV-specific CD4 and CD8 T-cell responses elicited by the therapeutic immunization strongly correlated with the reduction of the time of antiviral therapy (P = 0.0027 and 0.016, respectively). CONCLUSION: Our findings provide evidence that therapeutic immunization significantly impacts on HIV-1 replication. This translated into a decrease of up to 40% in the duration of exposure to antiretroviral drugs over 15 months of patients' follow-up. 相似文献
5.
Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults 总被引:3,自引:0,他引:3
Durier C Launay O Meiffrédy V Saïdi Y Salmon D Lévy Y Guillet JG Pialoux G Aboulker JP 《AIDS (London, England)》2006,20(7):1039-1049
BACKGROUND: HIV-1 lipopeptides have been developed by the French National Agency for AIDS Research (ANRS) for use as candidate vaccine against HIV since 1994. Between 1996 and 2005, four different lipopeptide constructs were tested alone or in combination with recombinant canarypox HIV vaccines in 10 trials conducted in France. The aim of this study was to review clinical safety of HIV lipopeptides. METHODS: A meta-analysis based on individual subject data examined clinical safety data collected in eight preventive trials and two therapeutic trials enrolling 200 HIV-1-uninfected healthy volunteers and 48 HIV-1-infected patients. RESULTS: Of 248 trial participants, eight (3.2%) did not complete follow-up: seven among the 200 healthy volunteers, and one among the 48 HIV-1 infected patients. During the 354 person-years of follow-up, 860 lipopeptides injections were administered. Local reactions were common. However, in trials where lipopeptides were tested without adjuvant and appropriate diluents, none of the vaccinees experienced severe local response. Systemic reactions were generally mild and transient. No grade 4 reaction was reported; 18 subjects experienced grade 3 systemic events related to the vaccination, mainly asthenia, fever, headache and arthralgia. Multivariate analysis showed that female sex, number of injections and diluent (more reactions in 5% glucose alone than in combination with Tris-HCl buffer) significantly increased systemic reactions related to the vaccination. CONCLUSION: These data demonstrate that reactogenicity and systemic safety of HIV lipopeptides vaccine are acceptable both in healthy volunteers and HIV-infected adults. 相似文献
6.
7.
Topouchian A Kapel N Larue-Achagiotis C Barbot L Tomé D Gobert JG Huneau JF 《Parasitology research》2005,96(5):326-330
This study aimed to explore the metabolic consequences of cryptosporidiosis in an acute experimental model both at the peak of infection and after parasite clearance. Four-day-old suckling rats were infected with 106 oocysts of Cryptosporidium parvum . At the peak of infection (day 8 PI), C. parvum resulted in a dramatic reduction both in nutrient intake (–50%) and body weight (16.3±5.2 vs 27.3±1.0 g, P<0.01) with a decrease in both lean body mass and adipose tissue. Muscular fractional and absolute synthesis rate were reduced (–15 and –55%, respectively). After parasite clearance (day 17 PI), body weight remained reduced in formerly infected animals (37.8±8.0 vs 47.8±4.2 g, P<0.01) whereas nutrient intake normalized and fractional synthesis rate slightly increased (+22%) compared to controls. Overall, our results show that the impact and consequences of cryptosporidiosis are far greater than generally appreciated, leading to major malnutrition in suckling rats. 相似文献
8.
9.
10.
In situ detection of antigen-specific tumor-infiltrating lymphocytes using newly designed tetramers 总被引:3,自引:0,他引:3
Bras-Gonçalves R Le Gal FA Avril MF Dalod M Connan F Chaboissier A Choppin J Guillet JG 《Journal of immunological methods》2003,280(1-2):103-111
We described a new process for the design of HLA tetramers using soluble MHC class I molecules purified from Epstein Barr Virus-transformed B cells. This method does not rely on genetic engineering and presents a significant advantage in view of the polymorphism of MHC class I molecules because tetramers can be produced with any HLA molecule. Here, we showed that our HLA-A*0201 tetramers provided experimental results similar to those obtained with tetramers made with recombinant MHC molecules. Moreover, they can be used to efficiently identify peptide-specific T cells from ex vivo PBMCs as well as from lymphocytes infiltrating human tumor. This innovative and simple method could be widely adopted, specially in diagnostic procedures for monitoring peptide-based immunotherapy. 相似文献